Publications found:
73,128
Sort by:
Global Human Growth Hormone Market Report: 2012 Edition
US$ 800.00
... idiopathic. Earlier, to deal with these predicaments, growth hormone (GH) used to be extracted from the human cadavers but, as time passed and evolution of ... day. The human growth hormone market (HGH) is monopolized by a few players viz. Pfizer, NovoNordisk, Eli Lilly and Roche. The global HGH report discusses ...
September 2012
42 pages
Analysis of Emerging Tumor Markers and Strategic Profiles of Leading Suppliers
US$ 2,800.00
... Stimulating Factors, Lymphokines, Immunohistochemical Stains and others. The report includes an overview of the clinical significance and market needs for both current and emerging tumor markers, as well as extensive listings of companies, universities and research centers developing or ...
September 2012
286 pages
Taiwan Medical Tourism Analysis and Forecast to 2015
US$ 800.00
Taiwan started to develop its medical tourism sector in earnest only four years ago. But its medical tourism has become one of the biggest attractions for mid to high income Chinese tourists. Other co...
September 2012
36 pages
Analyzing the Global CNS Market
US$ 650.00
... of their leading CNS drugs. Aruvians Rsearch analyzes the Global CNS Market in its research offering Analyzing the Global CNS Market. The report is ... next section, we analyze the global CNS market through a market overview and an analysis of the market by CNS drug classes. We also analyze the industry through ...
September 2012
200 pages
FirstImpact: FDA Approval of Aubagio
US$ 1,195.00
Following US approval of Aubagio (teriflunomide; Sanofi/Genzyme) for use in Relapsing Remitting Multiple Sclerosis patients (RRMS), FirstWord interviewed nearly 300 US-based neurologists within 24 hou...
September 2012
16 pages
Global Dialysis Market Report: 2012 Edition
US$ 800.00
... peritoneal dialysis market share, Baxter was the in the lead position. The current report presents the global dialysis market on both global and regional basis. The report also ...
August 2012
48 pages
Erythropoietin (EPO) Market Report: 2012 Edition
US$ 800.00
... known as rHuEPO (Recombinant Human Erythropoietin) manufactured using DNA. It is similar to the natural human EPO. In the pharmaceutical drug market, 5 variants of ESAs ... -delta and darbepoetin-alfa. This report provides a comprehensive analysis of the ESA/EPO product market of Japan and China. The competitive ...
August 2012
48 pages
World Sensors Market in Healthcare Applications (2012-2017), Global Forecast & Analysis - Segmentation by Type of Sensor, Monitoring, Therapeutic, Diagnostic and Others
US$ 3,390.00
... World Sensors Market in Healthcare Applications (2012-2017), Global Forecast & Analysis - Segmentation by Type of Sensor (Temperature, Pressure, Chemical, Flow, Level, Position, Image and Biosensors), ... , based on the extensive research study on the world sensors market in healthcare applications, aims at identifying the entire market and all its sub-segments through extensively ...
August 2012
402 pages
Personalized Medicine - A Global Market Overview
US$ 3,600.00
Description: Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a mor...
August 2012
350 pages
Malaysia Medical Tourism Analysis and Forecast to 2015
US$ 900.00
Malaysia has gained reputation as one of the preferred location for medical tourism by virtue of its highly efficient medical staff and modern healthcare facilities. Malaysia has seen an impressive gr...
August 2012
41 pages
Private Hospital Services Market In India
US$ 800.00
... ), Fortis Healthcare (Fortis), Global Hospitals (Global) and CARE Hospitals (CARE) are some of the leading players in Private Hospital Services market. The Private Hospital Services Market in India is expected to poise a high growth ... to private hospital market in India: India Hospital Services Market Overview Public & Private Hospital Infrastructure Human Resource Investment & Expansion Plans by leading Private Hospital Chain Demand in Tier II Cities: The New Growth Frontier for Private Hospitals
August 2012
85 pages
Analyzing the Medical Disposables Market in the US
US$ 500.00
Demand for disposable medical supplies in the United States is anticipated to rise substantially by 2016. The market has been ... incontinence products. Aruvians Rsearch analyzes the medical disposables market in the US in its research offering Analyzing the Medical Disposables Market in the US. The report ...
August 2012
115 pages
Brazil Healthcare - New Opportunities for Growth
US$ 1,000.00
Brazil is considered as one of the most lucrative healthcare market in Latin America with highest healthcare expenditure. Strong government support and high healthcare services demand are some of the...
August 2012
105 pages
Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module
US$ 4,995.00
Therapy Trends KOL Insight: Rheumatoid Arthritis analyses the current and predicted key issues, clinical advances and late-stage pipeline products in the international and US RA markets. KOL Insight g...
August 2012
245 pages
Global Renal Denervation Market Report: 2012 Edition
US$ 800.00
... ongoing trends in the respective market include Medtronic’s HTN-3 pivotal study, development of novel renal denervation devices, devising of baroreceptor stimulation ... Medical Inc. and Covidien. This RDN Market report attempts to elicit the rapidly evolving market by scrutinizing the novel technologies, product ...
July 2012
42 pages
REGENERON - Riding High on the Back of Eylea...
US$ 90.00
... ’s ability to buffer the setbacks in the pipeline. In today’s 2Q12 earnings, Regeneron (REGN) reported sales of $194m way above street expectations (our ...
July 2012
4 pages
VIVUS – Qsymia’s Launch and Ex-US Partnership = Growth Drivers
US$ 140.00
... launch by 4Q12 ahead of rival drug, Arena/Eisai's Belviq (loracaserin, 5-HT2C receptor agonist) should give Vivus (VVUS) the first mover advantage, as Qsymia ... , please read our report released on July 19, 2012 on VVUS, titled “Qsymia’s Launch and Ex-US Partnership = Growth Drivers
July 2012
3 pages
GLOBAL PHARMA SCREEN FOR TOP PICK
US$ 500.00
We recommend MRK and Roche as our Top pick from Global pharma space. NVS as well is interesting, trading at defensive valuations, but except ... they do one could see up to 30-40% upside from current levels. Our screening criteria is based on: Expected News flow from Pipeline and Potential ...
July 2012
21 pages
Shionogi - Dolutegravir Can Bring ‘Good Times’ Back to Shionogi!
US$ 140.00
... encouraging and similar outcome from four late stage studies can bring Dolutegravir in forefront of anti-HIV therapy – this is the first ... changing in anti-HIV regime, we expect dolutegravir has potential to cross $2.5b. In this report we have analyzed dolutegravir opportunity in mono-thx and in combination ...
July 2012
5 pages
Mitsubishi Tanabe - Collategene US Marketing Rights – A Bet to Get Trump Card for US!
US$ 90.00
Mitsubishi Tanabe (MT) announcement to acquire US marketing rights of Collategene (preparing PhIII, PAD, Anges) ... (MTP) - but are subject to PhIII outcome of Collategene. A solid data in PhIII will prompt MT to ... analyze that the concept and approach of Collategene carries an attractive ‘high-risk-high-reward ...
July 2012
3 pages
Competitor Analysis: B7 – CD28/CTLA-4 Pathway
US$ 370.00
... /CTLA-4 signaling family to treat autoimmune diseases or cancer. In addition, the report lists company-specific R&D pipelines of projects in the B7 – CD28/CTLA-4 pathway. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound ...
July 2012
35 pages
Sampling: A Key Business Driver in a Multi-channel Environment
US$ 595.00
... future of sampling is undoubtedly digital, but what are the best ways for brands to make this critical transition? Report Overview Sampling: A key business driver in a multi ... predictions for the future of product sampling. Sampling: A key business driver in a multi-channel environment is designed to help sales, marketing, and sampling logistics leaders learn best practices ...
July 2012
53 pages
Recreational, Outdoor, and Fitness GPS Solutions: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Recreational, Outdoor, and Fitness GPS Solutions in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are ...
July 2012
486 pages
Eisai, Belviq Approval – Implications on Eisai’s Bottom Line is Weak!
US$ 90.00
We continue with our Underperform rating on Eisai following approval of Belviq (lorcaserin, 5 HT 2C agonist, partnered with Arena) in the US. Despite ... (Qnexa has PDUFA date on 26th July 2012; we are expecting approval). Belviq administration is to be discontinued if 5% weight loss is not achieved within 12 ...
June 2012
3 pages
